

Nuno C Taveira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7265152/publications.pdf>

Version: 2024-02-01

115
papers

48,306
citations

145106

33
h-index

30277

107
g-index

124
all docs

124
docs citations

124
times ranked

65028
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolution of the prevalence and incidence of oral disorders in Portugal, 1990â€“2016: findings from the Global Burden of Disease 2016 Study. <i>Annals of Medicine</i> , 2024, 51, 67-67.	1.5	0
2	Antibody neutralization and its determinants in HIV-1 infected patients from Portugal: implications for vaccine design and efficacy. <i>Annals of Medicine</i> , 2024, 51, 89-89.	1.5	0
3	Structural elucidation and molecular dynamics study targeting the viral surface glycoproteins against HIV-2 infection. <i>Annals of Medicine</i> , 2024, 51, 151-151.	1.5	0
4	Broad Spectrum Functional Activity of Structurally Related Monoanionic Au(III) Bis(Dithiolene) Complexes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7146.	1.8	5
5	Anti-HIV-1 Activity of pepRF1, a Proteolysis-Resistant CXCR4 Antagonist Derived from Dengue Virus Capsid Protein. <i>ACS Infectious Diseases</i> , 2021, 7, 6-22.	1.8	3
6	Mapping routine measles vaccination in low- and middle-income countries. <i>Nature</i> , 2021, 589, 415-419.	13.7	71
7	Spiro-Î²-lactam BSS-730A Displays Potent Activity against HIV and Plasmodium. <i>ACS Infectious Diseases</i> , 2021, 7, 421-434.	1.8	11
8	Diagnosis of SARS-Cov-2 Infection by RT-PCR Using Specimens Other Than Naso- and Oropharyngeal Swabs: A Systematic Review and Meta-Analysis. <i>Diagnostics</i> , 2021, 11, 363.	1.3	44
9	Computational Modulation of the V3 Region of Glycoprotein gp125 of HIV-2. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1948.	1.8	3
10	Antibody response against selected epitopes in the HIV-1 envelope gp41 ectodomain contributes to reduce viral burden in HIV-1 infected patients. <i>Scientific Reports</i> , 2021, 11, 8993.	1.6	5
11	Synthesis and structure-activity relationships of new chiral spiro-Î²-lactams highly active against HIV-1 and Plasmodium. <i>European Journal of Medicinal Chemistry</i> , 2021, 219, 113439.	2.6	19
12	Probiotics in Oral Health and Disease: A Systematic Review. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 8070.	1.3	15
13	Inhibition of HIV replication through siRNA carried by CXCR4-targeted chimeric nanobody. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 2859-2870.	2.4	14
14	Genotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapy. <i>Aids</i> , 2020, 34, 483-486.	1.0	2
15	Global burden of 369 diseases and injuries in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1204-1222.	6.3	7,664
16	Global burden of 87 risk factors in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1223-1249.	6.3	3,928
17	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950â€“2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1160-1203.	6.3	890
18	Five insights from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1135-1159.	6.3	335

#	ARTICLE	IF	CITATIONS
19	Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain. <i>Scientific Reports</i> , 2020, 10, 13024.	1.6	1
20	Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2020, 395, 1779-1801.	6.3	72
21	Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance. <i>Nature Microbiology</i> , 2020, 5, 443-454.	5.9	114
22	Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2. <i>Journal of Infectious Diseases</i> , 2020, 221, 1962-1972.	1.9	14
23	A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies. <i>Vaccines</i> , 2020, 8, 171.	2.1	6
24	Pyromellitic dianhydride crosslinked soluble cyclodextrin polymers: Synthesis, lopinavir release from sub-micron sized particles and anti-HIV-1 activity. <i>International Journal of Pharmaceutics</i> , 2020, 583, 119356.	2.6	17
25	Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. <i>Nature Medicine</i> , 2020, 26, 750-759.	15.2	47
26	Predicting the evolution and control of the COVID-19 pandemic in Portugal. <i>F1000Research</i> , 2020, 9, 283.	0.8	7
27	Predicting the evolution and control of the COVID-19 pandemic in Portugal. <i>F1000Research</i> , 2020, 9, 283.	0.8	13
28	Spiro-Lactams as Novel Antimicrobial Agents. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 140-152.	1.0	16
29	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. <i>Nature</i> , 2019, 574, 353-358.	13.7	161
30	Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. <i>Lancet HIV</i> , the, 2019, 6, e831-e859.	2.1	341
31	HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study. <i>Scientific Reports</i> , 2019, 9, 5606.	1.6	22
32	PO 8597...NEUTRALISING AND NON-NEUTRALISING ANTIBODIES RESPONSE IN HIV-1-INFECTED INDIVIDUALS FROM MOZAMBIQUE. <i>BMJ Global Health</i> , 2019, 4, A61.2-A61.	2.0	0
33	InÂvitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2. <i>Antiviral Research</i> , 2019, 161, 85-89.	1.9	3
34	Clonal expansion across the seas as seen through CPLP-TB database: A joint effort in cataloguing <i>Mycobacterium tuberculosis</i> genetic diversity in Portuguese-speaking countries. <i>Infection, Genetics and Evolution</i> , 2019, 72, 44-58.	1.0	18
35	Mitochondrial DNA in human identification: a review. <i>PeerJ</i> , 2019, 7, e7314.	0.9	67
36	Trends in HIV/AIDS morbidity and mortality in Eastern Mediterranean countries, 1990–2015: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 123-136.	1.0	13

#	ARTICLE	IF	CITATIONS
37	Global, regional, and national age-sex-specific mortality and life expectancy, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1684-1735.	6.3	716
38	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1736-1788.	6.3	4,989
39	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1923-1994.	6.3	3,269
40	Population and fertility by age and sex for 195 countries and territories, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1995-2051.	6.3	294
41	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1789-1858.	6.3	8,569
42	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 2091-2138.	6.3	335
43	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1859-1922.	6.3	2,123
44	Noncovalent PEG Coating of Nanoparticle Drug Carriers Improves the Local Pharmacokinetics of Rectal Anti-HIV Microbicides. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 34942-34953.	4.0	32
45	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	6.3	638
46	Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women. <i>PLoS ONE</i> , 2018, 13, e0195744.	1.1	6
47	Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. <i>Scientific Reports</i> , 2018, 8, 12266.	1.6	16
48	Accidental Father-to-Son HIV-1 Transmission During the Seroconversion Period. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 857-862.	0.5	6
49	HIV-2 Envelope: Structure, Diversity, and Evolution. , 2018, , 945-949.		0
50	Genetic diversity, transmission dynamics and drug resistance of <i>Mycobacterium tuberculosis</i> in Angola. <i>Scientific Reports</i> , 2017, 7, 42814.	1.6	17
51	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990â€“2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 390, 231-266.	6.3	480
52	Assessment of the Cavidix ExaVir Load Assay for Monitoring Plasma Viral Load in HIV-2-Infected Patients. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2367-2379.	1.8	6
53	Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015â€“16: a modelling study. <i>Lancet Infectious Diseases, The</i> , 2017, 17, 330-338.	4.6	185
54	Potency of HIV-2-specific antibodies increase in direct association with loss of memory B cells. <i>Aids</i> , 2017, 31, 2431-2433.	1.0	6

#	ARTICLE	IF	CITATIONS
55	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1084-1150.	6.3	573
56	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1260-1344.	6.3	1,589
57	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1151-1210.	6.3	3,565
58	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1211-1259.	6.3	5,578
59	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1423-1459.	6.3	284
60	Donor-Recipient Identification in Para- and Poly-phyletic Trees Under Alternative HIV-1 Transmission Hypotheses Using Approximate Bayesian Computation. <i>Genetics</i> , 2017, 207, 1089-1101.	1.2	12
61	A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. <i>Journal of Virology</i> , 2017, 91, .	1.5	35
62	Computational Approach to Structural and Conformational Characterization of Viral Surface Glycoproteins of HIV-2. <i>Proceedings (mdpi)</i> , 2017, 1, 228.	0.2	0
63	Early infant diagnosis of HIV-1 infection in Luanda, Angola, using a new DNA PCR assay and dried blood spots. <i>PLoS ONE</i> , 2017, 12, e0181352.	1.1	8
64	Genetic diversity, transmission dynamics, and drug resistance of <i>Mycobacterium tuberculosis</i> in Luanda, Angola. <i>International Journal of Mycobacteriology</i> , 2016, 5, S38-S39.	0.3	1
65	A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support. <i>Retrovirology</i> , 2016, 13, 85.	0.9	13
66	Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors. <i>Aids</i> , 2016, 30, 1691-1701.	1.0	12
67	Rare HIV-1 Subtype J Genomes and a New H/U/CRF02_AG Recombinant Genome Suggests an Ancient Origin of HIV-1 in Angola. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 822-828.	0.5	11
68	On the contribution of Angola to the initial spread of HIV-1. <i>Infection, Genetics and Evolution</i> , 2016, 46, 219-222.	1.0	11
69	Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates. <i>Journal of Virology</i> , 2016, 90, 11062-11074.	1.5	12
70	P-B3–Evaluation of an in-house molecular HIV-1 Test to assess Mother-to-Child HIV-1 transmission in Angola (the APEHC cohort). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 73.	0.9	0
71	Development of water-soluble polyanionic carbosilane dendrimers as novel and highly potent topical anti-HIV-2 microbicides. <i>Nanoscale</i> , 2015, 7, 14669-14683.	2.8	33
72	Determinants of Highly Active Antiretroviral Therapy Duration in HIV-1-Infected Children and Adolescents in Madrid, Spain, from 1996 to 2012. <i>PLoS ONE</i> , 2014, 9, e96307.	1.1	7

#	ARTICLE	IF	CITATIONS
73	HIV-1 Diversity, Transmission Dynamics and Primary Drug Resistance in Angola. <i>PLoS ONE</i> , 2014, 9, e113626.	1.1	17
74	Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response. <i>Retrovirology</i> , 2013, 10, 110.	0.9	11
75	An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity. <i>Aids</i> , 2013, 27, 1081-1090.	1.0	25
76	HIV-2 Envelope: Structure, Diversity, and Evolution. , 2013, , 1-6.		1
77	Predictors of Attrition and Immunological Failure in HIV-1 Patients on Highly Active Antiretroviral Therapy from Different Healthcare Settings in Mozambique. <i>PLoS ONE</i> , 2013, 8, e82718.	1.1	21
78	HIV-2 susceptibility to entry inhibitors. <i>AIDS Reviews</i> , 2013, 15, 49-61.	0.5	3
79	Memory B-cell depletion is a feature of HIV-2 infection even in the absence of detectable viremia. <i>Aids</i> , 2012, 26, 1607-1617.	1.0	13
80	Baseline susceptibility of primary HIV-2 to entry inhibitors. <i>Antiviral Therapy</i> , 2012, 17, 565-570.	0.6	44
81	Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism. <i>Aids</i> , 2012, 26, 2275-2284.	1.0	23
82	Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A. <i>Journal of General Virology</i> , 2012, 93, 889-899.	1.3	56
83	Genetic Diversity and Drug Resistance Profiles in HIV Type 1- and HIV Type 2-Infected Patients from Cape Verde Islands. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 510-522.	0.5	6
84	HIV-1 Diversity and Its Implications in Diagnosis, Transmission, Disease Progression, and Antiretroviral Therapy. , 2012, , .		4
85	Evaluation of the diagnostic performance of the rapid test VIKIA HIV1/2 in a highly complex HIV-1 epidemic. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 71, 90-92.	0.8	7
86	Evolutionary and Structural Features of the C2, V3 and C3 Envelope Regions Underlying the Differences in HIV-1 and HIV-2 Biology and Infection. <i>PLoS ONE</i> , 2011, 6, e14548.	1.1	27
87	Origin and Epidemiological History of HIV-1 CRF14_BG. <i>PLoS ONE</i> , 2011, 6, e24130.	1.1	28
88	Potent and Broadly Reactive HIV-2 Neutralizing Antibodies Elicited by a Vaccinia Virus Vector Prime-C2V3C3 Polypeptide Boost Immunization Strategy. <i>Journal of Virology</i> , 2010, 84, 12429-12436.	1.5	22
89	HIV-2 Genetic Evolution in Patients with Advanced Disease Is Faster than That in Matched HIV-1 Patients. <i>Journal of Virology</i> , 2010, 84, 7412-7415.	1.5	26
90	Outbreak of Acute Respiratory Infection among Infants in Lisbon, Portugal, Caused by Human Adenovirus Serotype 3 and a New 7/3 Recombinant Strain. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1391-1396.	1.8	46

#	ARTICLE	IF	CITATIONS
91	Rapid clinical progression to AIDS and death in a persistently seronegative HIV-1 infected heterosexual young man. <i>Aids</i> , 2009, 23, 2359-2362.	1.0	12
92	Antiretroviral Drug Resistance Surveillance among Treatment-Naive Human Immunodeficiency Virus Type 1-Infected Individuals in Angola: Evidence for Low Level of Transmitted Drug Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3156-3158.	1.4	20
93	Highly divergent subtypes and new recombinant forms prevail in the HIV/AIDS epidemic in Angola: New insights into the origins of the AIDS pandemic. <i>Infection, Genetics and Evolution</i> , 2009, 9, 672-682.	1.0	44
94	HIV-1 Genetic Diversity and Transmitted Drug Resistance in Health Care Settings in Maputo, Mozambique. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 323-331.	0.9	25
95	The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients. <i>Retrovirology</i> , 2008, 5, 78.	0.9	23
96	Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression. <i>Aids</i> , 2008, 22, 2257-2265.	1.0	16
97	Synonymous Substitution Rates Predict HIV Disease Progression as a Result of Underlying Replication Dynamics. <i>PLoS Computational Biology</i> , 2007, 3, e29.	1.5	152
98	Use of a New Dual-Antigen Enzyme-Linked Immunosorbent Assay To Detect and Characterize the Human Antibody Response to the Human Immunodeficiency Virus Type 2 Envelope gp125 and gp36 Glycoproteins. <i>Journal of Clinical Microbiology</i> , 2006, 44, 607-611.	1.8	17
99	Evidence for negative selective pressure in HIV-2 evolution in vivo. <i>Infection, Genetics and Evolution</i> , 2005, 5, 239-246.	1.0	25
100	High Genetic Diversity of Human Immunodeficiency Virus Type 1 in Angola. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 306-310.	0.5	22
101	Synonymous Substitution Rates Predict HIV Disease Progression as a Result of Underlying Replication Dynamics. <i>PLoS Computational Biology</i> , 2005, preprint, e29.	1.5	1
102	Phylogenetic Demonstration of Two Cases of Perinatal Human Immunodeficiency Virus Type 2 Infection Diagnosed in Adulthood. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 1373-1376.	0.5	9
103	Seronegative infection and AIDS caused by an A2 subsubtype HIV-1. <i>Aids</i> , 2004, 18, 1071-1074.	1.0	13
104	Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection. <i>Virology</i> , 2003, 308, 225-232.	1.1	23
105	Construction and characterization of CD4-independent infectious recombinant HIV-2 molecular clones. <i>Virus Research</i> , 2003, 97, 159-163.	1.1	9
106	Evaluation of the Clinical Sensitivities of Three Viral Load Assays with Plasma Samples from a Pediatric Population Predominantly Infected with Human Immunodeficiency Virus Type 1 Subtype G and BG Recombinant Forms. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3361-3367.	1.8	37
107	Production and Characterization of a Mouse Monoclonal Antibody against the Gag p26 Protein of Human Immunodeficiency Virus Type 2: Identification of a New Antigenic Epitope. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1279-1283.	0.5	1
108	Perinatally acquired HIV-2 infection diagnosed at 15 and 24 years of age. <i>Aids</i> , 2001, 15, 2460-2461.	1.0	9

#	ARTICLE	IF	CITATIONS
109	Quantitation of Human Immunodeficiency Virus Type 2 DNA in Peripheral Blood Mononuclear Cells by Using a Quantitative-Competitive PCR Assay. <i>Journal of Clinical Microbiology</i> , 1999, 37, 453-456.	1.8	28
110	Virological and Molecular Demonstration of Human Immunodeficiency Virus Type 2 Vertical Transmission. <i>Journal of Virology</i> , 1998, 72, 3418-3422.	1.5	22
111	Vertical transmission of HIV-2. <i>Lancet, The</i> , 1997, 349, 177-178.	6.3	13
112	Amplification of full-length HIV-2 envelope genes. <i>Molecular and Cellular Probes</i> , 1996, 10, 91-98.	0.9	1
113	Molecular Characterization of the env Gene from a Non-Syncytium-Inducing HIV-2 Isolate (HIV-2ALI). <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 223-224.	0.5	12
114	Detection of HIV-1 DNA by polymerase chain reaction incorporation of digoxigenin-11-dUTP and hybridization to immobilized probes. <i>Molecular and Cellular Probes</i> , 1994, 8, 235-240.	0.9	2
115	Detection of HIV1 proviral DNA by PCR and hybridization with digoxigenin labelled probes. <i>Molecular and Cellular Probes</i> , 1992, 6, 265-270.	0.9	6